Citations

Clear

3053 citation(s) found for "Patel, A".

NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026
Gerds, Aaron T., Gotlib, J, Abdelmessieh, Peter, Ali, Haris, Castells, Mariana, Chernak, Brian , Espinoza-Gutarra, Manuel R., Revell, Rebecca, Green, Steven, Gundabolu, Krishna , Hexner, Elizabeth, Jamieson, Catriona H., Khan, Irum, Kuykendall, Andrew T., McMahon, Brandon, Mohan, Sanjay R., Nadiminti, Kalyan V., Oh, Stephen, Palmer, Jeanne, Patel, Ami B. , Patel, Anand A., Rein, Lindsay, Salit, Rachel, Sehl, Mary, Wadleigh, Martha, Wall, Sarah A., Bergman, Mary Anne, Hochstetler, Cindy, Patel, Anand , Patel, Anand , Gerds, Aaron T. , Gotlib, Jason , Ali, Haris , Espinoza‐Gutarra, Manuel , Green, S, Hexner, Elizabeth O. , Jain, Tania , Khan, Irum , Kuykendall, Andrew , Madanat, Yazan F. , Masárová, Lucia , Mohan, Sanjay R., Nadiminti, Kalyan, Palmer, Jeanne , Podoltsev, Nikolai , Salit, Rachel B. , Sehl, Mary E. , Talpaz, Moshe , Wadleigh, Martha , Wall, Sarah

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 9, 2026 | Volume: 24 | Issue: 7 | Pages: No page available

10.6004/jnccn.2026.0034 | PMID 42425157 Get It

The Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) are a group of heterogenous hematologic malignancies characterized by the proliferation of blood cells and consist of myelofibrosis, polycythemia vera, and essential thrombocythemia. The NCCN Guidelines for MPN were developed as a result of meetings convened by a multidisciplinary panel with expertise in MPN, with the aim of providing recommendations for the comprehensive care of adults with these diseases. The panel of experts convenes at least once a year to discuss requested changes to the Guidelines and to evaluate emerging data. These Guideline Insights focus on some of the recent updates for myelofibrosis.
Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology
Gradishar, W J, Moran, Meena S. , Abraham, Jame , Abramson, Vandana, Aft, Rebecca, Agnese, Doreen, Allison, Kimberly H., Anderson, Bethany, Bailey, Janet, Burstein, Harold J. , Chen, Nan , Chew, Helen, Dang, Chau, Giordano, Sharon H., Goetz, Matthew P., Jankowitz, Rachel C., Javid, Sara H., Leitch, A. Marilyn, LYONS, JANICE, McCloskey, Susie, McShane, Melissa , Patel, Sameer A. , Rosenberger, Laura H., Santa‐Maria, Cesar A. , Schneider, Bryan P., Smith, Mary Lou , Soliman, Hatem, Speers, Corey, Telli, Melinda L. , Wei, Mei , Wisinski, Kari B., Yellala, Amulya, Schonfeld, Ryan, Telli, Melinda L , Gradishar, William John, Abramson, Vandana G. , Agnese, Doreen Marie , Allison, Kimberly H. , Bailey, Janet E., Chew, Helen K. , Elias, Anthony , Giordano, Sharon H. , Goetz, Matthew P. , Jankowitz, Rachel C. , Javid, Sara H. , Leitch, A. Marilyn , Rosenberger, Laura H. , Rugo, Hope S. , Santa-Maria, Cesar Augusto , Schneider, Bryan P. , Soliman, Hatem, Speers, Corey , Wisinski, Kari B. , Yeung, Kay T. , Young, Jessica S. , Kumar, Rashmi

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 9, 2026 | Volume: 24 | Issue: 7 | Pages: No page available

10.6004/jnccn.2026.0033 | PMID 42425164 Get It

The NCCN Clinical Practice Guidelines for Breast Cancer include recommendations for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget’s disease, Phyllodes tumor, inflammatory breast cancer, and management of breast cancer during pregnancy. The panel convenes annually to update recommendations based on a review of recently published clinical trials. This selection from the NCCN Guidelines for Breast Cancer focuses on the recommendations for the management of recurrent or stage IV (M1) metastatic breast cancer. It summarizes the treatment strategies stratified by tumor biology, including hormone receptor status and HER2 expression, as well as clinical factors such as prior therapy and disease-free interval. Throughout all treatment lines, supportive care, quality of life preservation, toxicity minimization, and clinical trial participation are emphasized as integral components of patient care.
Early Versus Late Recurrence in Olfactory Neuroblastoma: A Multi‐Institutional Analysis of Predictive Risk Factors
Harris, Alexandria , Tang, Anthony, Fung, Nicholas , Champagne, Pierre‐Olivier, Fernandez-Miranda, Juan, Gardner, Paul A. , Hwang, Peter H. , Kalyvas, Aristotelis, Patel, Zara M. , Patel, Zara M., Celda, María Peris, Pinheiro-Neto, Carlos D., Sanusi, Olabisi, Thorp, Brian D., Gompel, Jamie J. Van, Zenonos, Georgios, Zwagerman, Nathan T., Bell, Diana, Kuan, Edward C., Geltzeiler, Mathew, Hwang, Peter H , Patel, Zara , Snyderman, Carl H , Wang, Eric W , Choby, Garret , Tang, Anthony , Almeida, João Paulo , Champagne, Pierre‐Olivier , Kalyvas, Aristotelis , Pinheiro‐Neto, Carlos , Sanusi, Olabisi , Thorp, Brian D. , Gompel, Jamie J. Van , Zenonos, Georgios A. , Zwagerman, Nathan T. , Bell, Diana , Kuan, Edward C , Geltzeiler, Mathew , Choby, Garret

Mayo Clinic

International Forum of Allergy & Rhinology | July 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/alr.70216 | PMID 42422976 Get It

ABSTRACT Background Olfactory neuroblastoma (ONB) exhibits variable recurrence patterns, with significant late recurrences occurring years after treatment. We investigated cutoff periods to define late recurrence and identified predictors that distinguish patients at risk of late recurrence from those considered cured. Methods From a multi‐institutional cohort of 219 ONB patients treated at nine centers, we analyzed 77 patients with documented recurrence. Using a 48‐month cutoff to define early (< 48 months) versus late (≥ 48 months) recurrence, we evaluated 35 clinical, anatomic, and treatment variables using Firth penalized logistic regression across three comparisons: (1) late versus early recurrence timing, (2) late recurrence versus no recurrence, and (3) early recurrence versus no recurrence. Results Thirty‐four of the 77 (44.2%) recurrences were classified as late. Among the 77 patients who recurred, smaller tumor volume (OR 0.243, p = 0.035) and lower novel Dulguerov staging (OR 0.802, p = 0.038) were associated with late, rather than early recurrence. When patients with late recurrence were compared to those who remained disease‐free, radiographic skull base bone involvement was the strongest independent predictor (OR 2.90, 95% CI 1.14–8.64, p = 0.025), and this effect strengthened after adjusting for tumor volume (OR 3.80, p = 0.029). Pathologic dural invasion (OR 3.29, p = 0.013), Kadish stage (OR 2.02, p = 0.026), and T‐stage (OR 1.32, p = 0.040) were also significant. Conclusions A 48‐month cutoff effectively stratifies ONB recurrence risk. Skull base bone involvement independently predicts recurrence when compared to nonrecurrent cases and uniquely persists as a risk factor for late recurrence. These findings establish skull base bone involvement as a novel biomarker for risk‐stratified surveillance protocols.
EGFR inhibition down-regulates MGMT and enhances responsiveness to temozolomide in glioblastoma
Nayab, Arifa , Mughal, Nouman , Angez, Meher , Xing, Sansi, Burma, Aarohan M. , Balla, Harshitha, Kizilbash, Sani H. , Yang, Xiaoyao , Maqbool, Muhammad Asad , Arain, Fazal Manzoor , Hussain, Azhar , Amir, Sahara , Singh, Deepti , Karmali, Alyiah , Somani, Saif, Patel, Toral , Patel, Ankur, Hatanpaa, Kimmo J. , YOUSSEF, M. S. K. , Shaikh, Nawal , Ye, C., Burma, Sandeep , Sarkaria, Jann N. , Majd, Nazanin , Saleh, Mansoor, Charest, Alain , Miller, C Ryan, Nabors, Burt , Kataru, Mary Susmitha , Tolbert, Chandler E. , Jimenez, Fatima, Enam, Syed Ather , Habib, Amyn A. , Guo, Gao , Arain, Fazal , Patel, Toral R , Youssef, Michael , Zhao, Dawen , Burma, Sandeep , Sarkaria, Jann N , Majd, Nazanin K , Charest, Alain , Nabors, Louis Burt , Kataru, Mary Susmitha , Tolbert, Chandler E , Enam, Syed Ather , Habib, Amyn A , Guo, Gao , Kizilbash, Sani H , Burma, Aarohan M , Amir, Sahara , Somani, Saif, Zhao, Dawen

Mayo Clinic

Science Translational Medicine | July 8, 2026 | Volume: 18 | Issue: 857 | Pages: No page available

10.1126/scitranslmed.adx8398 | PMID 42418561 Get It

Glioblastoma (GBM) is a devastating cancer with a dismal prognosis. Current treatment includes temozolomide (TMZ), which is more effective in about 50% of GBMs that have O 6 - methylguanine DNA methyltransferase ( MGMT ) promoter methylation. MGMT is a DNA repair protein that reverses TMZ-induced DNA damage. EGFR is a prime oncogene in GBM. Here, we report that EGFR inhibition induced the down-regulation of MGMT in GBM cells, revealing a previously unidentified link between EGFR signaling and response to TMZ. EGFR inhibition led to activation of two transcription factors, activator protein-1 (AP-1), which repressed MGMT transcription, and nuclear factor κB (NF-κB), which up-regulated MGMT transcription. EGFR inhibition also induced AP-1–mediated transcription of miR-616. miR-616 inhibited both MGMT translation and NF-κB activation. Thus, the overall effect of EGFR inhibition was down-regulation of MGMT expression. In addition, we provided an explanation for the prior failure of clinical trials that used concomitant EGFR tyrosine kinase inhibitors (TKIs) and TMZ. TMZ up-regulated MGMT, and concomitant treatment with EGFR TKIs and TMZ failed to down-regulate MGMT. However, pretreatment with EGFR TKIs followed by TMZ efficiently down-regulated MGMT and enhanced TMZ sensitivity in experimental models. Posttreatment tumor tissues from two clinical trials were used to validate these findings. We demonstrated that EGFR inhibitors induced down-regulation of MGMT in posttreatment resected tumor tissues from patients with GBM and the failure of EGFR inhibition to down-regulate MGMT if TMZ was used concomitantly. These data support using EGFR TKIs before TMZ treatment as a therapeutic approach in MGMT unmethylated GBM.
Consensus Guidelines for Staging and Surveillance Imaging in Cutaneous Squamous Cell Carcinoma
Kassamali, Bina , Schoenfeld, Jonathan D., Sethi, Rosh, Bakst, R H, Barker, C. A., Bradford, Carol R., Carr, David R., Chandra, Sunandana , Connolly, Karen L., Demer, Addison M. , Doonan, Bently, Emerick, Kevin, Friedman, Ben J. , Gali, Linna L., Galloway, Thomas J., Geiger, Jessica L., Kohen, Laurie, Koyfman, Shlomo, Kumar, Shweta Sharat, Learned, Kim O. , Leitenberger, Justin J., Lilley, Elizabeth J. , Lukens, John N. , Medina, Theresa , Mitra, Devarati , Ozog, David, Pashtan, Itai, Pham, Nancy , Powers, Molly, Srivastava, Divya, Taylor, Charlotte S., Witek, Matthew E. , Wysong, Ashley, Zander, David, Silk, Ann W., Jambusaria-Pahlajani, Anokhi, Ruiz, Emily S., Chen, Michelle , Kumar, Shweta S. , Schoenfeld, Jonathan D. , Barker, Christopher A. , Bhatt, Alok A. , Bradford, Carol R. , Bunch, Paul M. , Carr, David R., Carucci, John A. , Chen, Michelle , Connolly, Karen , Doonan, Bently P. , Emerick, Kevin S. , Friedman, Ben J. , Galloway, Thomas J. , Guenette, Jeffrey P. , Kelly, Hillary R. , Khushalani, Nikhil I. , Kohen, Laurie Linden, Leitenberger, Justin J. , Medina, Theresa M. , Pashtan, Itai , Patel, Vishal Anil , Srivastava, Divya , Swiecicki, Paul Loren , Wysong, Ashley, Silk, Ann Willman , Jambusaria‐Pahlajani, Anokhi , Ruiz, Emily S.

Mayo Clinic

JAMA Dermatology | July 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamadermatol.2026.2163 | PMID 42418212 Get It

Importance There is no consensus on staging and surveillance imaging for cutaneous squamous cell carcinoma (CSCC). Although imaging has been shown to affect management, broad recommendations from the National Comprehensive Cancer Network have led to variability in clinical practice. Objective To develop multidisciplinary consensus recommendations on the use of staging and surveillance imaging of localized CSCC. Evidence Review A multidisciplinary expert panel across academic and clinical practice settings convened a Delphi consensus, with 3 iterative survey rounds from January to June 2025. Data were analyzed from February 2025 to January 2026. Eligibility defined by at least 1 to 2 CSCC publications during the previous 5 years, involvement in a relevant clinical trial, experience treating at least 3 patients monthly with CSCC, and/or 5 years or longer of clinical practice. Fifty-four experts were invited and 45 (83%) completed all 3 rounds and were included in the final analysis. Structured Delphi surveys evaluated clinical scenarios, imaging modalities, and surveillance strategies for CSCC. Consensus and near-consensus recommendations were generated, defined as 80% or greater and 70% to 79% agreement, respectively. Findings The 45 participants (21 female individuals [47%] and 24 male individuals [53%]; 14 Asian individuals [31%], 1 multiracial individual [2%], and 30 White individuals [67%]) consisted of dermatology (15 [33%]), medical oncology (7 [16%]), radiation oncology (9 [20%]), radiology (9 [20%]), surgery (3 [7%]), and otolaryngology specialists (2 [4%]). The Delphi panel recommended staging and surveillance for CSCCs with at least a 15% risk of metastasis. Consensus or near consensus was reached to recommend staging and surveillance imaging for tumors with a concern for metastasis, bone invasion, invasion beyond subcutaneous fat, large-caliber nerve invasion, or a diameter of 4 cm or larger or the combination of tumors with poorly differentiated histology and any of the following: diameter of 2 cm or larger, lymphovascular invasion and subcutaneous fat invasion, or lymphovascular invasion and small-caliber perineural invasion. Computed tomography imaging was the preferred modality for nodal staging (38 [84%]) and surveillance (35 [78%]). For surveillance duration, consensus was reached to provide imaging for at least 2 years, and near consensus was reached for at least 3 years. Conclusions and Relevance This study provides an expert consensus–based framework to standardize imaging in localized CSCC that may inform future guidelines.
Loss of the kinases TBK1 and IKKε sensitizes target cancer cells to T cell killing through an IFN-γ–mediated inflammatory death program
Sun, N , Carr, Allison R. , Krogman, Erica N., Chawla, Yogesh , Zhong, Jun , Guttormson, Matthew C. , Chan, Mark , Hsu, Michelle A. , Dong, Haidong , Patel, Roosheel S. , Pandey, Akhilesh , Rogers, Laura M. , Ting, Adrian T. , Sun, Nicholas D , Bogunovic, Dusan , Pandey, Akhilesh , Dong, Haidong , Ting, Adrian T , Zhong, Jun , Rogers, Laura M , Chawla, Yogesh

Mayo Clinic

Science Signaling | July 7, 2026 | Volume: 19 | Issue: 945 | Pages: No page available

10.1126/scisignal.adz7366 | PMID 42412915 Get It

Cytotoxic T cells produce the cytokine interferon-γ (IFN-γ). We sought to determine whether IFN-γ directly kills target cells and found that T cells used IFN-γ to kill murine melanoma cells lacking the kinases TBK1 and IKKε. In the absence of both kinases, IFN-γ induced the production of TNF receptor 1 (TNFR1) and the sensor Z-DNA binding protein 1 (ZBP1) in the tumor cells to stimulate receptor-interacting protein kinase 1 (RIPK1)–dependent apoptosis in a cell-autonomous manner. IFN-γ also enhanced the activation of nuclear factor κB (NF-κB) signaling in a TNFR1-dependent manner in cells deficient in both TBK1 and IKKε. Because IFN-γ–induced apoptosis occurred in a transcription-dependent manner with slow kinetics, STAT1 and NF-κB cooperated to activate the expression of inflammatory genes in the dying cells. Thus, IFN-γ–induced cell death was accompanied by an inflammatory signature in the absence of TBK1 and IKKε. TBK1 and IKKε not only mediated the induction of type I IFN but also inhibited RIPK1-dependent death and NF-κB–dependent inflammation. Therefore, we propose that these kinases may have gained these intertwined functions so that cells infected by pathogens that produce antagonists of TBK1 and IKKε are eliminated by IFN-γ–secreting T cells in an inflammatory manner to compensate for the inhibition of type I IFN production.
How Are We Matching in ACL Reconstruction Research? A Systematic Review of Methods, Reporting, and Covariate Selection
Patel, Jay A. , Holle, Alejandro M. , Halpin, Brooke S. , Tummala, Sailesh V. , Patel, Jay R , Holle, Alejandro , Tummala, Sailesh V , Patel, Karan A. , Chhabra, Anikar

Mayo Clinic

Orthopaedic Journal of Sports Medicine | July 6, 2026 | Volume: 14 | Issue: 7 | Pages: No page available

10.1177/23259671261444318 | PMID 42416047 Get It

Background: Matching techniques such as direct covariate matching and propensity score matching (PSM) are increasingly used in anterior cruciate ligament reconstruction (ACLR) research to reduce bias in observational study designs. However, the rationale for covariate selection, consistency in methodological reporting, and patterns of matching practices remain unclear. Purpose: To systematically evaluate covariate matching practices in ACLR literature, including the types and number of covariates used, methodological transparency, and trends in matching strategies. Study Design: Systematic review. Methods: A systematic literature search of the PubMed, EMBASE, and Cochrane databases was conducted to evaluate covariate matching practices in the ACLR literature. A comprehensive search identified 798 unique studies, of which 97 met eligibility criteria. Data were extracted on study design, matching technique, covariate inclusion, reporting practices, and matching ratios. Descriptive and comparative statistics were used to summarize trends. Results: The 97 included studies encompassed 91,165 ACLRs. Most studies were retrospective (90.7%) and cohort in design (92.8%). PSM was used in 41 studies (42.3%), while 56 (57.7%) used direct matching. A total of 60 unique covariates were used across 76 different combinations. PSM studies used significantly more covariates than direct matching studies (6.17 ± 2.79 vs 3.75 ± 1.63; P < .0001), and database studies used more covariates than single-center studies (6.33 ± 2.89 vs 4.08 ± 1.96; P < .0001). The most commonly used covariates were age (96.9%), sex (84.5%), and body mass index (41.2%). Only 6 studies (6.2%) provided justification for covariate selection. The most frequent matching ratio was 1:1 (73.2%). While most studies reported descriptive statistics after matching (95.9%), only 10.3% did so before matching, and 13.4% failed to report prematching sample size. Conclusion: Matching practices in ACLR studies remain highly variable, with limited justification provided for covariate selection. PSM and database-based studies tend to incorporate a greater number of covariates, yet reporting of matching methodology is often inconsistent. To enhance the quality, reproducibility, and comparability of ACLR research, future studies should adopt standardized reporting practices for matching, including explicit descriptions of covariate selection, matching algorithms, balance diagnostics, and match ratios. These steps can serve as a foundation for a more unified research framework, enabling future studies to collectively generate higher quality, generalizable evidence for ACLR outcomes.
Real-World Outcomes with BCMA- and GPRC5D-Targeting Bispecific Antibodies in Plasma Cell Leukemia
Gaballa, Mahmoud R. , Julian, Kelley , Afrough, Aimaz , Hansen, Doris K. , Goel, Utkarsh , Corraes, Andre De Menezes Silva, Dima, Danai , Rana, Masooma , Hosoya, Hitomi , Mikkilineni, Lekha , Fogel, Lindsay , Raza, Shahzad, Zanwar, Saurabh , Sannareddy, Aishwarya, Borogovac, Azra , Green, Kimberly M , Biran, Noa, Shune, Leyla, Ouchveridze, Evguenia, DeJarnette, Shaun, Ferreri, Christopher J, Richards, Tiffany, Bal, Susan , Ye, Jing Christine, Shain, Kenneth H. , Harada, Ken , Avila, Gabriel De, Voorhees, Peter, Khouri, Jack , Sidana, Surbhi , Lin, Yi, Patel, Krina K. , Sborov, Douglas W. , Gaballa, Mahmoud , De Menezes Silva Corraes, Andre , Banerjee, Rahul , Zanwar, Saurabh S , Borogovac, Azra , Davis, James A , Green, Kimberly , Zolotov, Eli , Herr, Megan M. , Abid, Muhammad Bilal , Bal, Susan , Ali, Hossam M , Kaur, Gurbakhash , Shain, Kenneth H , Castaneda Puglianini, Omar , Hassan, Hamza , Anderson, Larry D , Khouri, Jack , Sidana, Surbhi , Portuguese, Andrew J , Janakiram, Murali , Lee, Hans C , Patel, Krina , Sborov, Douglas W , Dima, Danai , Hosoya, Hitomi , Rana, Masooma S , Julian, Kelley L , Hansen, Doris K , Corraes, Andre De Menezes Silva , Raza, Shahzad , Banerjee, Rahul , Pasvolsky, Oren , Sannareddy, Aishwarya , Davis, James A. , Biran, Noa , Zolotov, Eli , Shune, Leyla , Atrash, Shebli , Ferreri, Christopher J. , Richards, Tiffany, Abid, Muhammad Bilal , Ali, Hossam M. , Ye, Jing Christine, Richard, Shambavi , Kaur, Gurbakhash , Puglianini, Omar Castañeda , Rossi, Adriana , Hassan, Hamza , Anderson, Larry D. , Voorhees, Peter M. , Portuguese, Andrew J. , Janakiram, Murali , Lee, Hans C. , Grajales‐Cruz, Ariel

Mayo Clinic

Blood Advances | July 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2026020826 | PMID 42392158 Get It

Patients with plasma cell leukemia (PCL) are generally excluded from pivotal T-cell redirecting bispecific antibody (BsAb) trials. We evaluated real-world outcomes in a multicenter retrospective study of 122 patients with primary or secondary PCL across 15 academic centers, categorized as 'active' (≥5% circulating plasma cells within 30 days of BsAb initiation) or 'historical'. In a heavily pretreated population, patients received teclistamab (37%), elranatamab (11%), talquetamab as a line of therapy (Tal LOT, 42%), or talquetamab as bridging therapy to CAR-T (Tal Bridge, 11%). Cytokine release syndrome (CRS) was grade 1-2 in 56% and grade 3-4 in 4%, whereas neurotoxicity was grade 1-2 in 16% and grade 3-4 in 5%. Among 110 evaluable patients, the overall response rate (ORR) was 55%, including 61% with Tal LOT, 58% with Tal Bridge, 46% with elranatamab, and 33% with teclistamab. With a median follow-up of 8.3 months, talquetamab demonstrated superior survival. Tal LOT showed a median progression-free survival (mPFS) of 5.5 months and a median overall survival (mOS) of 11.5 months, and both were unreached in the Tal Bridge cohort. In contrast, teclistamab and elranatamab showed a mPFS of 1.2 and 1.6 months and mOS of 8.1 and 3.6 months, respectively (P=0.007, P=0.023). In active PCL, Tal LOT achieved mPFS/mOS of 6.9/12.2 months versus 0.7/1.4 months with teclistamab and 1.0/3.1 months with elranatamab, respectively (P&lt;0.001, P=0.002). Multivariable analysis associated active PCL with worse survival and Tal LOT with improved outcomes. BsAbs were safe in PCL, with talquetamab showing superior outcomes compared with BCMA-directed BsAbs.
Illustrative Integration of Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Data in Dose-Cohort Review for a Phase I Clinical Trial
Mead‐Harvey, Carolyn , Noble, Brie, Yee, Claire, Mazza, Gina, Langlais, Blake, Patel, Sheetal, Trask, Peter, Rogak, Lauren , Basch, Ethan, Dueck, Amylou, Thanarajasingam, Gita , Noble, Brie N. , Mazza, Gina L , Langlais, Blake, Basch, Ethan , Dueck, Amylou C.

Mayo Clinic

No container title available | July 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-10072400/v1 | PMID 42427853 Get It

Abstract Background This secondary analysis of a phase I clinical trial illustrates integrated summary and visualization of Common Terminology Criteria for Adverse Events (CTCAE) data and Patient-Reported Outcomes version of the CTCAE (PRO-CTCAE) data at baseline and through the first cycle of treatment for tolerability review during dose-cohort evaluation in a phase I trial. Methods This study uses data from a phase I clinical trial of patients with relapsed or refractory acute myeloid leukemia. Through iterative feedback from clinicians and statisticians, we developed a summary of cycle 1 PRO-CTCAE and CTCAE data for the first dose-level cohort. This summary is intended to demonstrate reporting that would be reviewed to inform a decision about proceeding to the next dose level in a dose escalation trial. Results Cycle 1 CTCAE and PRO-CTCAE data for 4 patients enrolled in the first dose cohort are summarized as narrative and tabular summaries and visualized using swimmer and butterfly plots. In this cohort, 3/4 (75%) patients had at least one CTCAE grade 3 or higher adverse event, and all 4 (100%) patients had at least one PRO-CTCAE composite score of 3 during cycle 1. All 4 (100%) patients had at least one symptom for which PRO-CTCAE suggested greater symptom burden than was reflected in CTCAE. Conclusions In this illustrative summary of a dose cohort, PRO-CTCAE complemented CTCAE reporting by capturing patient-reported symptomatic burden that was not always fully reflected by clinician-graded adverse events. Reviewing PRO-CTCAE and CTCAE data together during dose-cohort evaluation may enrich discussions on safety and tolerability in phase I trials.
Noninvasive Respiratory Support for Adult Patients with Acute Respiratory Failure. An Official American Thoracic Society Clinical Practice Guideline
Goel, N N, Ferreyro, Bruno L. , Pitre, Tyler , Lewis, K, Homer-Bouthiette, Collin , Angriman, Federico , Dourado, Letícia K., Drake, M G, Eaton, Tammy L. , Esbrook, Cheryl L., Frat, Jean-Pierre , Grieco, D L, LeTourneau, William, Mosier, Jarrod, Patel, Bhakti K. , Qadir, Nida , Riviello, Elisabeth , Roca, Oriol , Twagirumugabe, T, Munshi, L, Rochwerg, Bram, Care, on behalf of the American Thoracic Society Assembly on Critical, Rissman, Jason, Drake, Matthew G. , Kawano-Dourado, Letícia , Goel, Neha N , Lewis, Kimberley , Kawano-Dourado, Leticia , Drake, Matthew G , Grieco, Domenico L , Mosier, Jarrod M , Patel, Bhakti K , Twagirumugabe, Theogene , Vranas, Kelly C , Munshi, Laveena , Rochwerg, Bram , Lewis, Kimberley , Mosier, Jarrod , Qadir, Nida , Patel, Bhakti K

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | June 29, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ajrccm/aamag302 | PMID 42371750 Get It

Abstract Background Acute hypoxemic and hypercapnic respiratory failure are among the most common reasons for ICU admission and need for invasive mechanical ventilation. Noninvasive respiratory support (NIRS) strategies—including high-flow nasal cannula (HFNC), noninvasive ventilation (NIV), and continuous positive airway pressure (CPAP)—may prevent intubation, improve outcomes, and reduce ICU utilization. However, there is uncertainty regarding optimal patient and modality selection, resulting in variable implementation. There are no clinical practice guidelines comprehensively addressing the use of the different noninvasive respiratory support strategies across the spectrum of acute respiratory failure. Objective To update and develop new evidence-based clinical practice recommendations informing noninvasive respiratory support use, including HFNC, NIV and CPAP, in adults with acute respiratory failure. Methods A multidisciplinary panel used the GRADE approach to address four PICO questions related to the use of NIRS for hypoxemic and hypercapnic respiratory failure, preoxygenation for intubation, and post-extubation respiratory support. Recommendations were informed by several systematic reviews and network meta-analyses. Results The panel made a strong recommendation for HFNC and a conditional recommendation for NIV or CPAP for adults with acute hypoxemic respiratory failure with close monitoring for the need for escalation of respiratory support, based primarily on effects on need for intubation. For acute hypercapnic respiratory failure, the panel made a strong recommendation for NIV to reduce mortality and need for invasive mechanical ventilation, and a conditional recommendation for HFNC only in patients with less severe hypercapnia and with mild acidemia (eg, pH &gt; 7.25), provided that close monitoring and prompt escalation to NIV are available. The panel made a strong recommendation for HFNC or NIV for preoxygenation prior to endotracheal intubation to prevent peri-intubation hypoxemia. The panel also issued a risk-based recommendation, suggesting HFNC for low-risk patients and NIV for high-risk patients to reduce the need for re-intubation following extubation after critical illness. Conclusions Noninvasive respiratory support strategies are effective in improving outcomes in a range of clinical scenarios. We provide evidence-based recommendations, which can be further informed by patient risk, institutional capacity, and interface tolerance.